Messenger RNA Therapies Are Finally Fulfilling Their Promise
Instructing our cells to make specific proteins could control influenza, autoimmune diseases, even cancer
Drew Weissman is a professor of vaccine research at the University of Pennsylvania. The nucleoside-modified mRNA-lipid-nanoparticle vaccine platform his laboratory created is used in COVID-19 vaccines made by Pfizer-BioNTech and Moderna. Weissman receives royalties from a patent for nucleoside-modified mRNA that is licensed by those two companies.
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account